Skip to content
People six months and older should have one of the updated COVID-19 vaccines released by Pfizer-BioNTech and Moderna, under the recommendation approved Sept. 12 […]
CDC recommends everyone get the updated COVID-19 vaccines Read More »
Kintara Therapeutics, Biotechnology Innovation Organization (BIO) member, is an innovative, patient-centered biotech company that is working to change the game when it comes to
Kintara Q&A: novel treatments for aggressive cancers Read More »
September is a perfect time to schedule your flu vaccine– as well as COVID and, if you’re eligible, the new RSV vaccines. And with
What you need to know about the upcoming flu season Read More »
The U.S. Food and Drug Administration (FDA) approved Pfizer’s respiratory syncytial virus vaccine, Abrysvo, to prevent RSV in infants. The August 21 decision comes
FDA approves first vaccine to prevent RSV in infants Read More »
As many legislatures across the country go into recess, it is time for Bio.News’ mid-year state policy roundup. In the realm of sustainability and
What’s been happening in the state legislatures on agriculture policy Read More »
The state legislatures have been as busy as ever in 2023—especially in the health care sector. Now, as many legislatures across the country are
What’s been happening in state legislatures on health care Read More »
Respiratory syncytial virus, or RSV, innovations are big news this year—and for good reason. The biotech industry has finally cracked the code for treating
Codagenix Q&A: Diversifying vaccination options for patients Read More »
The mifepristone saga is entering its next chapter. On August 16, 2023, the U.S. Court of Appeals for the Fifth Court for the Northern
Appeals court rules to restrict access to mifepristone Read More »
Childhood vaccination rates get a lot of attention, but it’s equally important to work on adult vaccination rates, too. “Right now, as a number
National Immunization Awareness Month: A conversation with GSK on adult vaccine access Read More »
Merck on July 27 announced positive Phase 3 results for a new pneumococcal conjugate vaccine, which targets several varieties of bacteria that cause pneumococcal pneumonia.
Merck’s pneumococcal vaccine for adults shows promise in Phase 3 trial Read More »
